Trial Profile
12-week, multicenter, double-blind, randomized, placebo-controlled, parallel-group study to investigate the efficacy, pharmacodynamic and safety of two doses of alfuzosin (0.1 mg/kg/day; 0.2 mg/kg/day) in the treatment of children and adolescents 2 – 16 years of age with elevated detrusor leak point pressure of neuropathic etiology followed by a 40-week open-label extension
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 05 Oct 2021
Price :
$35
*
At a glance
- Drugs Alfuzosin (Primary)
- Indications Detrusor instability
- Focus Registrational; Therapeutic Use
- Acronyms ALFACHIN
- Sponsors Sanofi
- 02 Jul 2012 New trial record